Standard chemotherapy + Imatinib
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Lymphoblastic Leukemia
Conditions
Acute Lymphoblastic Leukemia, Philadelphia Chromosome
Trial Timeline
Dec 1, 2005 → Mar 3, 2017
NCT ID
NCT00287105About Standard chemotherapy + Imatinib
Standard chemotherapy + Imatinib is a phase 2 stage product being developed by Novartis for Acute Lymphoblastic Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00287105. Target conditions include Acute Lymphoblastic Leukemia, Philadelphia Chromosome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00287105 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Lymphoblastic Leukemia